Phio Pharmaceuticals Corp. (PHIO): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Phio Pharmaceuticals Corp. (PHIO) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. phio20260717_8k.htm false 0001533040 0001533040 2026-07-21 2026-07-21 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event repo
How this was made
The 30-second read
Why it matters
The company increased board size to six and added Dr. R. Todd Plott, M.D., including standard indemnification and non-employee director compensation/equity awards. No financial guidance, trial results, or corporate transaction is included.
Market read
This is governance/board composition news with limited direct impact on near-term cash flows or clinical/product milestones.
What to watch
Traders may overreact to director headlines; the filing provides no details on committee influence, timelines for strategic initiatives, or any material transaction.
Background
The filing is an SEC Form 8-K (Item 5.02) reporting a director/officer change and related compensatory arrangements.
Ticker impact
Phio Pharmaceuticals appointed dermatologist R. Todd Plott, M.D. to its board effective July 20, 2026, with standard director compensation and indemnification.
Low likelihood of a sustained move; any reaction is likely modest and short-lived unless tied to a broader strategic shift not disclosed here.
The 8-K discloses a director appointment and related indemnification/compensation terms, without any operational, financial, or clinical catalyst or guidance change.
Market effects
Limited read-across to biotech governance practices; no sector-wide regulatory or clinical signal disclosed.
No specific regional market linkage beyond Nasdaq-listed issuer governance update.
No global operational or partnership implications stated.
Counterpoint
The appointment may be largely procedural, with no evidence in the filing of new strategy, financing, or clinical acceleration.
Key entities
- issuerPhio Pharmaceuticals Corp.
Nasdaq-listed company filing the 8-K and appointing a new director.
- director_appointeeR. Todd Plott, M.D.
Board-certified dermatologist appointed to the board and Governance Committee until the 2026 annual meeting.
- board_committeeGovernance Committee
Committee membership assigned to the newly appointed director.
